Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection

• Published in: World journal of hepatology 2021-01, Vol.13 (1), p.109-119
• Main Authors: de Bitencorte, Jóice Teixeira, Rech, Tássia Flores, Lunge, Vagner Ricardo, Dos Santos, Deivid Cruz, Álvares-da-Silva, Mário Reis, Simon, Daniel
• Format: Article
• Language: English
• Subjects: Case Control Study
• ISSN: 1948-5182; 1948-5182
• DOI: 10.4254/wjh.v13.i1.109

Hepatitis C virus (HCV) infection is a public health concern worldwide. Several factors, including genetic polymorphisms, may be evolved in the progression of HCV infection to liver diseases. Interferon lambdas (IFNLs) modulate the immune response during viral infections. IFNLs induce antiviral activity, interfering in the viral replication by promoting the expression of several genes that regulate immunological functions. The interferon lambda-4 ( ) rs12979860 polymorphism, which is characterized by a C to T transition in intron 1, is associated with spontaneous and treatment-induced clearance of HCV infection and may play a role in the development of HCV-associated liver diseases, including hepatocellular carcinoma (HCC). To investigate the association of rs12979860 polymorphism with fibrosis, cirrhosis, and HCC in patients with chronic HCV infection. This study was comprised of 305 chronic HCV-infected patients (53 fibrosis, 154 cirrhosis, and 98 HCC cases). The control group was comprised of 260 HCV-negative healthy individuals. The rs12979860 polymorphism was genotyped using the TaqMan assay. Fibrosis was diagnosed based on liver biopsy findings, while cirrhosis was diagnosed through clinical, laboratory, anatomopathological, and/or imaging data. HCC was diagnosed through imaging tests, tumor, and/or anatomopathological markers. The T allele was observed in the three groups of patients (fibrosis, cirrhosis, and HCC) at a significantly higher frequency when compared with the control group ( = 0.047, < 0.001, and = 0.01, respectively). Also, genotype frequencies presented significant differences between the control group and cirrhosis patients ( < 0.001) as well as HCC patients ( = 0.002). The risk analysis was performed using the codominant and dominant T allele models. In the codominant model, it was observed that the CT genotype showed an increased risk of developing cirrhosis in comparison with the CC genotype [odds ratio (OR) = 2.53; 95% confidence interval (CI): 1.55-4.15; < 0.001] as well as with HCC (OR = 2.54; 95%CI: 1.44-4.56; = 0.001). A similar result was observed in the comparison of the TT CC genotype between the control group and cirrhosis group (OR = 2.88; 95%CI: 1.44-5.77; = 0.001) but not for HCC patients. In the dominant T allele model, the CT + TT genotypes were associated with an increased risk for progression to cirrhosis (OR = 2.60; 95%CI: 1.63-4.19; < 0.001) and HCC (OR = 2.45; 95%CI: 1.42-4.31; = 0.001). These findings suggest t